A 58-year-old woman from Delhi presents with a 2-month history of epigastric pain radiating to the back, unintentional weight loss of 6 kg, and recent-onset diabetes mellitus. She denies jaundice or pale stools. On examination, she is cachectic with mild epigastric tenderness. Serum amylase and lipase are normal. CT abdomen shows a 3.5 cm hypoattenuating mass in the pancreatic body with loss of fat planes around the superior mesenteric artery (SMA) and portal vein (PV). There is no evidence of distant metastases. CA 19-9 is 245 U/mL. Endoscopic ultrasound (EUS) with fine-needle aspiration (FNA) confirms adenocarcinoma. What is the most likely stage and appropriate management?

Explanation

## Clinical Presentation Analysis This patient presents with classic **locally advanced pancreatic cancer**: - Body/tail location (not head, so no obstructive jaundice) - Epigastric pain radiating to back (visceral pain, retroperitoneal involvement) - New-onset diabetes (paraneoplastic or tumor mass effect) - Weight loss and cachexia (advanced disease) - **Loss of fat planes around SMA and PV** — hallmark of vascular involvement - No distant metastases ## TNM Staging & Resectability Classification ```mermaid flowchart TD A[Pancreatic cancer]:::outcome --> B{Distant metastases?}:::decision B -->|Yes| C[Stage IV: Metastatic]:::urgent B -->|No| D{Vascular involvement?}:::decision D -->|No involvement| E[Resectable: Stage IIA/IIB]:::outcome D -->|SMA/PV contact <180°| F[Borderline resectable: Stage IIB]:::outcome D -->|>180° contact or encasement| G[Locally advanced: Stage III]:::outcome G --> H[Neoadjuvant therapy]:::action F --> I{Fit for surgery?}:::decision I -->|Yes| J[Neoadjuvant chemotherapy]:::action I -->|No| K[Palliative chemotherapy]:::action ``` ## Resectability Criteria (NCCN / AHPBA) | Resectability | SMA/PV Contact | Celiac/Hepatic Artery | Distant Metastases | | --- | --- | --- | --- | | **Resectable** | No contact or <180° | No involvement | None | | **Borderline Resectable** | <180° contact (touching) | No involvement | None | | **Locally Advanced** | >180° contact or encasement | Involvement or encasement | None | | **Metastatic** | Any | Any | Present | **Key Point:** "Loss of fat planes" around SMA/PV indicates **borderline-resectable to locally advanced disease**. This patient requires neoadjuvant therapy. ## Why This Is Stage IIB (Borderline/Locally Advanced) **High-Yield:** The AJCC 8th edition classifies pancreatic cancer as: - **Stage IIA:** T3 N0 M0 (resectable, no nodal involvement) - **Stage IIB:** T3 N1 M0 or T4 N0 M0 (vascular involvement ± nodes, locally advanced) - **Stage III:** Unresectable (>180° vascular involvement, encasement) - **Stage IV:** M1 (distant metastases) This patient has **T4 (vascular involvement) N? M0** = **Stage IIB**. ## Management: Neoadjuvant FOLFIRINOX **Key Point:** Borderline-resectable and locally advanced pancreatic cancer benefit from **neoadjuvant chemotherapy** because: 1. **Downsizing:** Shrinks tumor and may convert to resectable 2. **Early treatment of micrometastases:** Systemic therapy upfront 3. **Improved survival:** FOLFIRINOX (5-FU, leucovorin, irinotecan, oxaliplatin) is superior to gemcitabine 4. **Assess chemosensitivity:** Patients who progress on neoadjuvant therapy are spared surgery 5. **Better tolerability:** Neoadjuvant therapy given while patient is fit; postoperative chemotherapy often not tolerated **Mnemonic: FOLFIRINOX** — **F**luorouracil, **O**xaliplatin, **L**eucovorin, **F**luorouracil (bolus + infusion), **I**rinotecan, **N**ot gemcitabine (for borderline/locally advanced). ## Restaging After Neoadjuvant Therapy **Clinical Pearl:** After 2–3 months of neoadjuvant FOLFIRINOX: - Repeat CT/MRI to assess response - EUS to reassess vascular involvement - If converted to resectable → proceed to surgery (distal pancreatectomy + splenectomy for body/tail tumors) - If still unresectable or progressive → palliative chemotherapy ## Why Distal Pancreatectomy? For body/tail tumors, **distal pancreatectomy with splenectomy** is the standard resection (preserves pancreatic head and duodenum). Whipple is reserved for head tumors. [cite:NCCN Guidelines Pancreatic Cancer 2023; Harrison 21e Ch 297]